Q3 sales strongly grew +19% to €3,724m, primarily driven by the Sigma-Aldrich acquisition as organic growth was levelled out by negative FX developments. The gross profit margin dropped from 69.9% to 66.4% as a consequence of the acquisition. EBITDA strongly increased by +23% to €1,110m and net profit attributable to shareholders went up +26% to €457m. After the weak development in Q2, operating CF caught up in Q3 (+22% to €1,067m) based on the strong operating performance
15 Nov 2016
Healthcare and Life Science see profitability push; guidance lifted
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthcare and Life Science see profitability push; guidance lifted
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
15 Nov 2016 -
Author:
Martin Schnee -
Pages:
3
Q3 sales strongly grew +19% to €3,724m, primarily driven by the Sigma-Aldrich acquisition as organic growth was levelled out by negative FX developments. The gross profit margin dropped from 69.9% to 66.4% as a consequence of the acquisition. EBITDA strongly increased by +23% to €1,110m and net profit attributable to shareholders went up +26% to €457m. After the weak development in Q2, operating CF caught up in Q3 (+22% to €1,067m) based on the strong operating performance